6096 Frequency of KRAS/BRAF mutations as predictive markers for Cetuximab in Japanese colorectal cancer patients

T.Yokota; N.Shibata; T.Ura; D.Takahari; K.Shitara; K.Muro; Y.Yatabe

首页> 外文期刊>European Journal of Cancer Supplements >6096 Frequency of KRAS/BRAF mutations as predictive markers for Cetuximab in Japanese colorectal cancer patients

【24h】

6096 Frequency of KRAS/BRAF mutations as predictive markers for Cetuximab in Japanese colorectal cancer patients

机译：6096 KRAS / BRAF突变频率作为日本大肠癌患者西妥昔单抗的预测指标

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
T.Yokota; N.Shibata; T.Ura; D.Takahari; K.Shitara; K.Muro; Y.Yatabe;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer [J] . SoedaH., ShimodairaH., WatanabeM., International journal of clinical oncology . 2013,第4期

机译：KRAS，BRAF和PIK3CA突变作为伊立替康和奥沙利铂难治性转移性结直肠癌患者西妥昔单抗疗效的预测指标的临床实用性
2. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer [J] . Hiroshi Soeda, Hideki Shimodaira, Mika Watanabe, International Journal of Clinical Oncology . 2013,第4期

机译：KRAS，BRAF和PIK3CA突变作为伊立替康和奥沙利铂难治性转移性结直肠癌患者西妥昔单抗疗效的预测指标的临床实用性
3. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT [J] . DiBartolomeoM., PietrantonioF., PerroneF., Targeted oncology . 2014,第2期

机译：缺少KRAS，NRAS，BRAF和TP53突变可改善接受西妥昔单抗，奥沙利铂和UFT治疗的老年转移性结直肠癌患者的预后
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Glucose deprivation selects for KRAS and BRAF mutations in colorectal cancer. [D] . Yun, Jihye. 2009

机译：葡萄糖剥夺选择结直肠癌中的KRAS和BRAF突变。
6. KRAS codon 61 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer [O] . F Loupakis, A Ruzzo, C Cremolini, 2009

机译：KRAS 61、146和BRAF密码子突变预测KRAS 12和13野生型转移性结直肠癌对西妥昔单抗加伊立替康的耐药性
7. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer [O] . Loupakis F, Ruzzo A, Cremolini C, 2009

机译：KRAS 61、146和BRAF密码子突变预测KRAS 12和13野生型转移性结直肠癌对西妥昔单抗加伊立替康的耐药性

6096 Frequency of KRAS/BRAF mutations as predictive markers for Cetuximab in Japanese colorectal cancer patients

著录项

相似文献

相关主题

期刊订阅